Genopathy
Gene-Disorder Association · Article
Gene
EPHA5
EPH Receptor A5
Disorder
Lung Cancer
First reported 1950
Manually curatedApproved treatment annotated
Association Review

In brief

The association between EPHA5 (EPH Receptor A5) and Lung Cancer is reported, with clinical genetic testing available.

Sources 1
Clinical variants 0
Symptoms 13
Compounds 1
Trials 311of 3,366 via EPHA5 compounds
Publications 0
01
At a glance

Association overview

A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.

Request access
02
Provenance

Evidence and sources

1 source

Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.

Request access
03
EPHA5

The gene

2 source summaries

A gene summary alongside the source descriptions it was distilled from.

Request access
04
Lung Cancer

The disorder

31 database identifiers

The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).

Request access
05
Phenotype

Clinical features

3 clinical features

The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.

Request access
06
Interventions

Therapeutics

1 compound or drug

Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.

Request access
07
Human studies

Clinical trials

3,366 clinical trials

Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.

Request access
08
Provenance

References & sources

9 references

Every source and publication cited across this dossier, as one numbered reference list.

Request access